AZURE Trial Update - Dr. Robert Coleman

Description: For more updates visit

Dr. Robert Coleman with updates from ECC 2013 on the AZURE Trial. ZOL reduced disease recurrence in bone and, consistent with other studies, had a favourable effect on both invasive DFS and OS in postmenopausal women. However, in all other women an excess of events outside bone resulted in no overall effect of ZOL on disease outcomes in the total study population.
Shared By : oncologyeducation
Posted on : 10/07/13
Added : 6 years ago
Category : Other